COVID-19 VACCINE NEWS
MORE +
MEDIA
COVID-19 PODCAST
MORE +
MORE +
MEDIA
MORE +
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
COVID-19 PODCAST
MORE +
Listen now
Listen now
Listen now

Australia's Vaccine Agreements

  • Pre
    Clinical
  • Clinical
    Phase I
  • Clinical
    Phase II
  • Clinical
    Phase III
  • Post-Licensure Surveillance
    Phase IV

Australia has entered into 5 agreements for the supply of COVID-19 vaccines. Details of these vaccines can be found below, noting that the University of Oxford/AstraZeneca and the Pfizer/BioNTech COVID-19 vaccines have been granted provisional registration from the TGA and are currently being rolled out within Australia. The Novavax COVID-19 vaccine candidate is still in phase III clinical trials and will only be supplied if it is proved safe and effective and meets the strict criteria for registration by the TGA. The Moderna COVID-19 vaccine is currently in use internationally, with supply to Australia anticipated in the later part of 2021, following approval by the TGA.

 

COVAX Facility

The COVAX Facility is a global initiative designed to support rapid, fair and equitable access to COVID-19 vaccines. It allows all participating countries, regardless of income levels, to have equal access to a portfolio of vaccines once they have been developed. COVAX is coordinated by Gavi with help from member countries, the Coalition for Epidemic Preparedness Innovations (CEPI), the World Health Organization and UNICEF.

Further information

Novavax COVID-19 vaccine

Phase III
Phase 3
Platform
Protein based vaccine (nanoparticle-based vaccine)
Route
Intramuscular injection
Presentation
To be confirmed
Reconstitution required
To be confirmed
Schedule
2 doses, 21 days apart
Storage requirements
Storage, transport and handling at 2-8°C
Common side effects
Headache, fatigue and myalgia
Further information

Pfizer | BioNTech COVID-19 vaccine

Phase IV
Post-Licensure Surveillance
Platform
Genetic vaccine (mRNA)
Route
Intramuscular injection
Presentation
Multi dose vial (once reconstituted contains 5 doses of 0.3ml per dose)
Reconstitution required
Yes. Once thawed, dilute with 1.8 mL of sterile 0.9% sodium chloride to give 5 doses of 0.3 ml per dose
Schedule
2 doses, 3-6 weeks apart
Storage requirements
Ultra cold chain storage at -90°C to -60°C. Please refer to manufacturers instructions for further details
Common side effects
Mild to moderate pain at the injection site, fatigue, headache and muscle aches
Further information

University of Oxford | AstraZeneca COVID-19 vaccine

Phase IV
Post-Licensure Surveillance
Platform
Viral vector vaccine
Route
Intramuscular injection
Presentation
Multi dose vial (contains 10 doses of 0.5ml per dose)
Reconstitution required
No
Schedule
2 doses, 4-12 weeks apart
Storage requirements
Storage, transport and handling at 2-8°C
Common side effects
Pain and tenderness at the injection site, fatigue, headache, and flu-like symptoms
Further information

Moderna COVID-19 Vaccine

Phase IV
Post-Licensure Surveillance
Platform
Genetic vaccine (mRNA)
Route
Intramuscular injection
Presentation
Multi-dose vial (contains 10 doses of 0.5ml)
Reconstitution required
No
Schedule
2 doses 28 days apart
Storage requirements
Storage at between -25°C and -15°C, once thawed can be stored between 2°C and 8°C for up to 30 days
Common side effects
Pain at the injection site, tiredness, headache, muscle and joint pain, chills, fever, swollen lymph nodes in the same arm as the injection, nausea and vomiting
Further information